{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:39Z","timestamp":1789516839664,"version":"build-2803163510"},"reference-count":252,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.maturitas.2022.08.008","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T02:15:32Z","timestamp":1661825732000},"page":"65-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group"],"prefix":"10.1016","volume":"166","author":[{"given":"Nicol\u00e1s","family":"Mendoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"de la Viuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pluvio","family":"Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Baquedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pl\u00e1cido","family":"Llaneza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"S\u00e1nchez-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visitaci\u00f3n \u00c1lvarez","family":"de Frutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Andraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Barriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zully","family":"Ben\u00edtez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Bombas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa. Jes\u00fas","family":"Cancelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camil Castelo","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Doval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fasero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Fiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor C.","family":"Garello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Genazzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa. \u00c1ngeles","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios G.","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misericordia","family":"Guinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Rolando","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rosa","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Lete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lubi\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An\u00edbal","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Pedreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"P\u00e9rez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Pl\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Presa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Quereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Ribes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"S\u00e1nchez-Capilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"S\u00e1nchez-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Tinahones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Calaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2022.08.008_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.maturitas.2016.06.001","article-title":"Revised global consensus statement on menopausal hormone therapy","volume":"91","author":"de Villiers","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2022.04.008","article-title":"Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society","volume":"163","author":"Lambrinoudaki","year":"2022","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0015","first-page":"109","article-title":"IMS Recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric 2016"},{"issue":"11","key":"10.1016\/j.maturitas.2022.08.008_bb0020","first-page":"1362","article-title":"hormone therapy position statement of The North American Menopause Society","volume":"25","author":"The","year":"2017","journal-title":"Menopause 2018"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0025","series-title":"Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone","year":"2010"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.maturitas.2021.03.009","article-title":"Eligibility criteria for Menopausal Hormone Therapy (MHT): a consortium of scientific societies for the use of MHT in women with medical conditions. Research protocol","volume":"148","author":"Mendoza","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0035","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0045","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0055","series-title":"Version 5.4, The Cochrane Collaboration","author":"Manager (RevMan) [Computer program]","year":"2020"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0060","author":"Sch\u00fcnemann"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0065","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to 12 www.eurosurveillance.org making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.maturitas.2022.08.008_bb0070","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and BREAST CANCER incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and BREAST CANCER incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women\u2019s Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.maturitas.2022.08.008_bb0080","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0085","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women\u2019s Health Initiative Randomized Trials","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0090","first-page":"123","article-title":"A systematic review and meta-regression analysis to examine the \u2018timing hypothesis\u2019 of hormone replacement therapy on mortality, coronary heart disease, and stroke","volume":"22","author":"Nudy","year":"2019","journal-title":"Int. J. Cardiol. Heart Vasc."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0095","doi-asserted-by":"crossref","first-page":"20631","DOI":"10.1038\/s41598-020-77534-9","article-title":"A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.maturitas.2022.08.008_bb0100","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0105","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0115","doi-asserted-by":"crossref","first-page":"m3873","DOI":"10.1136\/bmj.m3873","article-title":"Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases","volume":"371","author":"Vinogradova","year":"2020","journal-title":"BMJ."},{"issue":"10204","key":"10.1016\/j.maturitas.2022.08.008_bb0120","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet."},{"issue":"9980","key":"10.1016\/j.maturitas.2022.08.008_bb0125","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","author":"Beral","year":"2015","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.maturitas.2022.08.008_bb0130","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1538-7836.2012.04919.x","article-title":"Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study","volume":"10","author":"Sweetland","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13643-016-0294-5","article-title":"Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis","volume":"5","author":"Asie","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0140","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1055\/s-0037-1614156","article-title":"Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)","volume":"84","author":"Hoibraaten","year":"2000","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0145","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/gme.0b013e3181f9f7c3","article-title":"Hormone therapy and recurrence of venous thromboembolism among postmenopausal women","volume":"18","author":"Oli\u00e9","year":"2011","journal-title":"Menopause."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"7655","key":"10.1016\/j.maturitas.2022.08.008_bb0155","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0160","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2141.2010.08128.x","article-title":"Reproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology","volume":"149","author":"Ohira","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0165","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1538-7836.2010.03839.x","article-title":"Hormone replacement therapy and the risk of venous thromboembolism: a population-based study","volume":"8","author":"Renoux","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","article-title":"Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis","volume":"168","author":"Rovinski","year":"2018","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0175","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.ATV.0000018301.91721.94","article-title":"Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease","volume":"22","author":"Herrington","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"13","key":"10.1016\/j.maturitas.2022.08.008_bb0180","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0185","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1055\/s-0037-1613857","article-title":"Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy","volume":"83","author":"Lowe","year":"2000","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0190","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.0007-1048.2002.03356.x","article-title":"Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis","volume":"116","author":"Rosendaal","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0195","doi-asserted-by":"crossref","first-page":"E106","DOI":"10.1177\/1076029610387587","article-title":"The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study","volume":"17","author":"Douketis","year":"2011","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"22","key":"10.1016\/j.maturitas.2022.08.008_bb0200","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1161\/CIRCULATIONAHA.105.565556","article-title":"Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration","volume":"112","author":"Straczek","year":"2005","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.maturitas.2022.08.008_bb0205","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.0000000000002059","article-title":"Age-specific association of migraine with cryptogenic TIA and stroke: population-based study","volume":"85","author":"Li","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-5122(00)00215-2","article-title":"Course of primary headaches during hormone replacement therapy","volume":"38","author":"Nappi","year":"2001","journal-title":"Maturitas"},{"issue":"9","key":"10.1016\/j.maturitas.2022.08.008_bb0215","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1526-4610.2002.02215.x","article-title":"Hormone supplementation differently affects migraine in postmenopausal women","volume":"42","author":"Facchinetti","year":"2002","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0220","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/01.gme.0000227399.53192.f5","article-title":"Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches","volume":"13","author":"Nappi","year":"2006","journal-title":"Menopause."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0225","doi-asserted-by":"crossref","unstructured":"Boardman HMP, Hartley L, Eisinga A, Main C, Roqu\u00e9 i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015, Issue 3. Art. No.: CD002229. DOI: https:\/\/doi.org\/10.1002\/14651858.CD002229.pub4.","DOI":"10.1002\/14651858.CD002229.pub4"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0230","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2005.12.015","article-title":"Randomized trial of hormone therapy in women after coronary bypass surgery: evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries","volume":"189","author":"Ouyang","year":"2006","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.maturitas.2022.08.008_bb0235","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1056\/NEJM200008243430801","article-title":"Effects of estrogen replacement on the progression of coronary-artery atherosclerosis","volume":"343","author":"Herrington","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"9350","key":"10.1016\/j.maturitas.2022.08.008_bb0240","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(02)12001-0","article-title":"Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial","volume":"360","author":"Cherry","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.amjcard.2004.09.021","article-title":"Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease","volume":"95","author":"Bibbins-Domingo","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0250","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0197-2456(02)00237-4","article-title":"Women\u2019s angiographic vitamin and estrogen trial: design and methods","volume":"23","author":"Hsia","year":"2002","journal-title":"Control. Clin. Trials"},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0255","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa030830","article-title":"Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women","volume":"349","author":"Hodis","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.maturitas.2022.08.008_bb0260","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa010534","article-title":"A clinical trial of estrogen-replacement therapy after ischemic stroke","volume":"345","author":"Viscoli","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.maturitas.2022.08.008_bb0265","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/eurheartj\/ehl183","article-title":"Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study","volume":"27","author":"Collins","year":"2006","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.maturitas.2022.08.008_bb0270","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1471-0528.2002.01544.x","article-title":"A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study","volume":"109","author":"Clarke","year":"2002","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0275","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/GME.0000000000000345","article-title":"Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins","volume":"22","author":"Berglind","year":"2015","journal-title":"Menopause"},{"issue":"12","key":"10.1016\/j.maturitas.2022.08.008_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051580","article-title":"Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction\u2013a nationwide cohort study","volume":"7","author":"Bretler","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-135-1-200107030-00003","article-title":"Postmenopausal hormone use and secondary prevention of coronary events in the nurses\u2019 health study. a prospective, observational study","volume":"135","author":"Grodstein","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0290","doi-asserted-by":"crossref","unstructured":"Khan MA, Liu MW, Singh D, Pal A, Chio FL, Lawson D, Dean LS. Long-term (three years) effect of estrogen replacement therapy on major adverse cardiac events in postmenopausal women after intracoronary stenting. Am. J. Cardiol. 2000 Aug 1;86(3):330-3. doi: https:\/\/doi.org\/10.1016\/s0002-9149(00)00926-7.","DOI":"10.1016\/S0002-9149(00)00926-7"},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(01)01329-8","article-title":"Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up","volume":"38","author":"Alexander","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0300","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0735-1097(01)01551-0","article-title":"Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women","volume":"38","author":"Angeja","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0305","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1161\/STROKEAHA.114.006668","article-title":"Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an analysis from the atrial fibrillation follow-up investigation of rhythm management trial","volume":"45","author":"Apostolakis","year":"2014","journal-title":"Stroke."},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0310","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0735-1097(03)00938-0","article-title":"Hormone replacement therapy is associated with improved survival in women with advanced heart failure","volume":"42","author":"Lindenfeld","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0315","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1067\/mtc.2002.126225","article-title":"Hormone replacement therapy is associated with improved survival in women undergoing coronary artery bypass grafting","volume":"124","author":"Nussmeier","year":"2002","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"13","key":"10.1016\/j.maturitas.2022.08.008_bb0320","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension","volume":"112","author":"White","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0325","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","article-title":"Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension","volume":"48","author":"White","year":"2006","journal-title":"Hypertension."},{"issue":"9","key":"10.1016\/j.maturitas.2022.08.008_bb0330","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0895-7061(02)02980-1","article-title":"Additive effect of drospirenone\/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril","volume":"15","author":"Preston","year":"2002","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0335","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjhyper.2004.12.003","article-title":"Effects of drospirenone\/17-beta estradiol on BP and potassium balance in hypertensive postmenopausal women","volume":"18","author":"Preston","year":"2005","journal-title":"Am. J. Hypertens."},{"issue":"3 Pt 1","key":"10.1016\/j.maturitas.2022.08.008_bb0340","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/01.gme.0000243572.63322.f7","article-title":"Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on BP and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide","volume":"14","author":"Preston","year":"2007","journal-title":"Menopause"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2022.08.008_bb0345","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/09513590701584956","article-title":"Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory BP in healthy postmenopausal women: a 1-year, randomized, prospective study","volume":"23","author":"Kaya","year":"2007","journal-title":"Gynecol. Endocrinol."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0350","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1291\/hypres.26.369","article-title":"Effects of hormone replacement therapy on office and ambulatory BP in Japanese hypertensive postmenopausal women","volume":"26","author":"Sumino","year":"2003","journal-title":"Hypertens. Res."},{"issue":"10 Pt 1","key":"10.1016\/j.maturitas.2022.08.008_bb0355","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0895-7061(99)00074-6","article-title":"Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women","volume":"12","author":"Modena","year":"1999","journal-title":"Am. J. Hypertens."},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0360","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.jhh.1001431","article-title":"The effect of hormone replacement therapy on arterial BP and vascular compliance in postmenopausal women with arterial hypertension","volume":"16","author":"Kawecka-Jaszcz","year":"2002","journal-title":"J. Hum. Hypertens."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MBP.0b013e32830d4b60","article-title":"Low-dose transdermal hormone therapy does not interfere with the BP of hypertensive menopausal women: a pilot study","volume":"13","author":"de Carvalho","year":"2008","journal-title":"Blood Press Monit."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0370","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.jhh.1000938","article-title":"A randomised placebo controlled trial of the effects of tibolone on BP and lipids in hypertensive women","volume":"14","author":"Lloyd","year":"2000","journal-title":"J. Hum. Hypertens."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0375","first-page":"638","article-title":"Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus","volume":"82","author":"Andersson","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0380","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/cmt.5.3.286.292","article-title":"Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus","volume":"5","author":"Araujo","year":"2002","journal-title":"Climacteric."},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0385","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s001250050758","article-title":"Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM","volume":"40","author":"Brussaard","year":"1997","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0390","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5122(00)00164-X","article-title":"Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial","volume":"37","author":"Cornu","year":"2000","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0395","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0168-8227(01)00297-2","article-title":"Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy","volume":"54","author":"Darko","year":"2000","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0400","first-page":"48","article-title":"Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes","volume":"86","author":"Friday","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000134955.93951.D5","article-title":"Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance","volume":"110","author":"Howard","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0410","doi-asserted-by":"crossref","first-page":"1e9","DOI":"10.7326\/0003-4819-138-1-200301070-00005","article-title":"Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen\/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial","volume":"138","author":"Kanaya","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0415","doi-asserted-by":"crossref","first-page":"27e34","DOI":"10.1111\/j.1365-2265.2006.02679.x","article-title":"Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes","volume":"66","author":"Kernohan","year":"2007","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0420","doi-asserted-by":"crossref","first-page":"1794e800","DOI":"10.1016\/j.metabol.2010.05.012","article-title":"Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status","volume":"59","author":"Lamon-Fava","year":"2010","journal-title":"Metabolism"},{"issue":"14","key":"10.1016\/j.maturitas.2022.08.008_bb0425","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/archinte.161.14.1772","article-title":"The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial","volume":"161","author":"Manning","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0430","doi-asserted-by":"crossref","first-page":"682e9","DOI":"10.1046\/j.1365-2265.2003.01906.x","article-title":"Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?","volume":"59","author":"McKenzie","year":"2003","journal-title":"Clin. Endocrinol."},{"issue":"8","key":"10.1016\/j.maturitas.2022.08.008_bb0435","first-page":"1111","volume":"84","author":"Mosnier-Pudar","year":"1991","journal-title":"Arch. Mal. Coeur Vaiss."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0440","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1210\/jcem.86.3.7297","article-title":"The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study","volume":"86","author":"Perera","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.maturitas.2022.08.008_bb0445","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2337\/diacare.22.9.1401","article-title":"Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study","volume":"22","author":"Samaras","year":"1999","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.maturitas.2022.08.008_bb0450","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/ijms17091388","article-title":"Effects of hormone therapy on oxidative stress in postmenopausal women with metabolic syndrome","volume":"17","author":"S\u00e1nchez-Rodr\u00edguez","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0455","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1463-1326.2004.00294.x","article-title":"Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes","volume":"6","author":"Scott","year":"2004","journal-title":"Diabetes. Obes. Metab."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0460","first-page":"134","article-title":"Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance","volume":"60","author":"Sumino","year":"2003","journal-title":"Horm. Res."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0465","doi-asserted-by":"crossref","first-page":"319e24","DOI":"10.1053\/meta.2001.20201","article-title":"Hormone-replacement therapy increases s\u00e8rum paraoxonase arylesterase activity in diabetic postmenopausal women","volume":"50","author":"Sutherland","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0470","doi-asserted-by":"crossref","first-page":"430e8","DOI":"10.1016\/j.maturitas.2005.07.008","article-title":"The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes","volume":"53","author":"Thunell","year":"2006","journal-title":"Maturitas"},{"issue":"23","key":"10.1016\/j.maturitas.2022.08.008_bb0475","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.4103\/0366-6999.194646","article-title":"Effect of half-dose and standard-dose conjugated equine estrogens combined with natural progesterone or dydrogesterone on components of metabolic syndrome in healthy postmenopausal women: a Randomized Controlled Trial","volume":"129","author":"Xue","year":"2016","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0480","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-5122(99)00112-7","article-title":"The effects of hormone replacement therapy on plasma lipids in type II diabetes","volume":"34","author":"Manwaring","year":"2000","journal-title":"Maturitas"},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0485","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2337\/diacare.24.7.1144","article-title":"Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the Northern California Kaiser Permanente Diabetes Registry","volume":"24","author":"Ferrara","year":"2001","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0490","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/01.CIR.0000042701.17528.95","article-title":"Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanent Diabetes Registry, 1995-8","volume":"107","author":"Ferrara","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0495","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.maturitas.2018.12.012","article-title":"Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women","volume":"121","author":"Kim","year":"2019","journal-title":"Maturitas."},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0500","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.2337\/diacare.26.10.2810","article-title":"Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes","volume":"26","author":"Newton","year":"2003","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0505","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0002-9149(03)00284-4","article-title":"Hormone replacement therapy and risk of acute myocardial infarction in postmenopausal women with diabetes mellitus","volume":"91","author":"Gami","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0510","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2337\/diacare.25.10.1675","article-title":"Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III)","volume":"25","author":"Crespo","year":"2002","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0515","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/meta.2001.24878","article-title":"Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women","volume":"50","author":"Sites","year":"2001","journal-title":"Metabolism."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0520","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.fertnstert.2005.01.131","article-title":"Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women","volume":"84","author":"Osmana\u011fao\u011flu","year":"2005","journal-title":"Fertil. Steril."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0525","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1538-7836.2006.01933.x","article-title":"Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study","volume":"4","author":"Canonico","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0530","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1572-0241.2007.01700.x","article-title":"Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease","volume":"103","author":"Kane","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0535","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.20463","article-title":"Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure","volume":"40","author":"Di Martino","year":"2004","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0540","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gut.2006.101931","article-title":"Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy","volume":"56","author":"Codes","year":"2007","journal-title":"Gut."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0545","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.gme.0000172271.78314.6d","article-title":"Neutral effect of prolonged transdermal hormone therapy on liver function of postmenopausal women with chronic active hepatitis","volume":"12","author":"Rinaldi","year":"2005","journal-title":"Menopause."},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0550","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0555","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"9407","key":"10.1016\/j.maturitas.2022.08.008_bb0560","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u2013is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0565","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0570","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0378-5122(01)00211-0","article-title":"A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy","volume":"39","author":"Marttunen","year":"2001","journal-title":"Maturitas."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0575","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.GME.0000061806.76067.E9","article-title":"Estrogen replacement therapy in breast cancer survivors: a matched-controlled series","volume":"10","author":"Decker","year":"2003","journal-title":"Menopause."},{"issue":"9","key":"10.1016\/j.maturitas.2022.08.008_bb0580","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/cncr.10913","article-title":"Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study","volume":"95","author":"Vassilopoulou-Sellin","year":"2002","journal-title":"Cancer."},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0585","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5694\/j.1326-5377.2002.tb04835.x","article-title":"Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality","volume":"177","author":"Durna","year":"2002","journal-title":"Med. J. Aust."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0590","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000055319","article-title":"Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates","volume":"60","author":"Beckmann","year":"2001","journal-title":"Oncology."},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0595","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O\u2019Meara","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0600","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0605","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000421-200012000-00001","article-title":"Breast cancer survival and hormone replacement therapy: a cohort analysis","volume":"23","author":"DiSaia","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0610","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0002-9378(96)70594-X","article-title":"Hormone replacement therapy in breast cancer survivors: a cohort study","volume":"174","author":"DiSaia","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0615","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.maturitas.2020.06.021","article-title":"No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)","volume":"142","author":"Cai","year":"2020","journal-title":"Maturitas."},{"issue":"19","key":"10.1016\/j.maturitas.2022.08.008_bb0620","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0625","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","article-title":"Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study","volume":"155","author":"Kotsopoulos","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"31","key":"10.1016\/j.maturitas.2022.08.008_bb0630","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.maturitas.2022.08.008_bb0635","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol."},{"issue":"35","key":"10.1016\/j.maturitas.2022.08.008_bb0640","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0645","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3892\/ol.2011.461","article-title":"Impact of postoperative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy","volume":"3","author":"Li","year":"2012","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0650","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0655","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","article-title":"Hormone replacement therapy and survival after surgery for ovarian cancer","volume":"302","author":"Eeles","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0660","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00042192-200101000-00012","article-title":"Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival","volume":"8","author":"Ursic-Vrscaj","year":"2001","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0665","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0670","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/13697137.2013.806472","article-title":"The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China","volume":"16","author":"Wen","year":"2013","journal-title":"Climacteric"},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0675","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/AOG.0000000000001396","article-title":"Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival","volume":"127","author":"Power","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.maturitas.2022.08.008_bb0680","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.4103\/0366-6999.182835","article-title":"Efficacy of postoperative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma","volume":"129","author":"Zhang","year":"2016","journal-title":"Chin. Med. J."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0685","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study","volume":"24","author":"Barakat","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0690","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ijgc-00009577-200603000-00054","article-title":"Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?","volume":"16","author":"Ayhan","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0695","first-page":"555","article-title":"Estrogen replacement therapy in endometrial cancer patients: a matched control study","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0700","first-page":"11","article-title":"Hormone therapy effect in postmenopausal women with history of endometrial cancer","volume":"79","author":"Arteaga-G\u00f3mez","year":"2011","journal-title":"Ginecol. Obstet. Mex."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0705","first-page":"326","article-title":"Estrogen replacement therapy in the patient treated for endometrial cancer","volume":"67","author":"Creasman","year":"1986","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0710","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0090-8258(90)90171-G","article-title":"Estrogen replacement therapy following treatment for stage I endometrial carcinoma","volume":"36","author":"Lee","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0715","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","article-title":"Estrogen replacement in surgical stage I and II endometrial cancer survivors","volume":"175","author":"Chapman","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0720","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e72","article-title":"The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients","volume":"29","author":"Lim","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0725","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e51","article-title":"Effects of hormone therapy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database","volume":"30","author":"Cho","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0730","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormone replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol. Oncol."},{"issue":"36","key":"10.1016\/j.maturitas.2022.08.008_bb0735","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1200\/JCO.2006.08.0580","article-title":"Hormone replacement therapy and survival after colorectal cancer diagnosis","volume":"24","author":"Chan","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0740","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bjc.2015.224","article-title":"Reproductive and hormonal factors and mortality among women with colorectal cancer in the NIH-AARP Diet and Health Study","volume":"113","author":"Arem","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0745","first-page":"979","article-title":"Hormone replacement therapy in relation to survival in women diagnosed with colon cancer","volume":"14","author":"Mandelson","year":"2003","journal-title":"Cancer Causes Control"},{"issue":"10","key":"10.1016\/j.maturitas.2022.08.008_bb0750","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/ijc.31228","article-title":"Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: a population-based study in Sweden","volume":"142","author":"Ji","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0755","first-page":"467","article-title":"Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA)","volume":"10","author":"Slattery","year":"1999","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0760","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.2005.02.9827","article-title":"Hormone replacement therapy is associated with decreased survival in women with lung cancer[J]","volume":"24","author":"Ganti","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0765","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3747\/co.v16i3.302","article-title":"Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?","volume":"16","author":"Ayeni","year":"2009","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0770","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JTO.0000000000000077","article-title":"Survival in women with NSCLC: the role of reproductive history and hormone use","volume":"9","author":"Katcoff","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"18","key":"10.1016\/j.maturitas.2022.08.008_bb0775","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/cncr.24475","article-title":"Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population","volume":"115","author":"Huang","year":"2009","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103735","article-title":"Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study","volume":"9","author":"Clague","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0785","first-page":"372","article-title":"Meta-analysis for the effect of hormone replacement therapy on survival rate in female with lung cancer","volume":"45","author":"Li","year":"2020","journal-title":"Zhong Nan Da Xue Bao Yi Xue Ban"},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0790","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/sj.bjc.6601595","article-title":"Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma","volume":"90","author":"MacKie","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0795","doi-asserted-by":"crossref","first-page":"100955","DOI":"10.1016\/j.pmedr.2019.100955","article-title":"The association of age at menopause and all-cause and cause-specific mortality by race, postmenopausal hormone use, and smoking status","volume":"15","author":"Malek","year":"2019","journal-title":"Prev. Med. Rep."},{"issue":"17","key":"10.1016\/j.maturitas.2022.08.008_bb0800","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM198510243131702","article-title":"Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study","volume":"313","author":"Wilson","year":"1985","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0805","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0895-4356(94)90014-0","article-title":"A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women","volume":"47","author":"Mann","year":"1994","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0810","first-page":"1","article-title":"Smoking, estradiol metabolism and hormone replacement therapy","volume":"53","author":"Mueck","year":"2003","journal-title":"Arzneimittelforschung."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0815","first-page":"45","article-title":"Smoking, estradiol metabolism and hormone replacement therapy","volume":"3","author":"Mueck","year":"2005","journal-title":"Curr. Med. Chem. Cardiovasc. Hematol. Agents"},{"key":"10.1016\/j.maturitas.2022.08.008_bb0820","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijgo.2005.02.023","article-title":"Twenty-four hour ambulatory blood pressure in postmenopausal smokers and non-smokers on hormone therapy","volume":"90","author":"Driul","year":"2005","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0825","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1677\/joe.0.1620265","article-title":"Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking","volume":"162","author":"Geisler","year":"1999","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0830","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF00544361","article-title":"Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives","volume":"28","author":"Abernethy","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0835","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/clpt.1984.114","article-title":"Imipramine disposition in users of oral contraceptive steroids","volume":"35","author":"Abernethy","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"issue":"13","key":"10.1016\/j.maturitas.2022.08.008_bb0840","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM198204013061307","article-title":"Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids","volume":"306","author":"Abernethy","year":"1982","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0845","first-page":"771","article-title":"Amenorrhea following rifampin administration during oral contraceptive use","volume":"44","author":"Altschuler","year":"1974","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0850","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.2007.03084.x","article-title":"Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects","volume":"65","author":"Andrews","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0855","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00563105","article-title":"The effect of rifampicin on norethisterone pharmacokinetics","volume":"15","author":"Back","year":"1979","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0860","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0010-7824(80)90125-0","article-title":"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women","volume":"21","author":"Back","year":"1980","journal-title":"Contraception."},{"issue":"7","key":"10.1016\/j.maturitas.2022.08.008_bb0865","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00228-004-0796-2","article-title":"Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives","volume":"60","author":"Baisini","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0870","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","article-title":"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive","volume":"65","author":"Barditch-Crovo","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0875","first-page":"131","article-title":"Rifampicin interference with oral contraceptives","volume":"8","author":"Bessot","year":"1977","journal-title":"J. Med. Strasb."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0880","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2012.01.010","article-title":"Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women","volume":"86","author":"Blode","year":"2012","journal-title":"Contraception."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0885","first-page":"189","article-title":"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man","volume":"85","author":"Bolt","year":"1977","journal-title":"Acta Endocrinol."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0890","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00562654","article-title":"Effect of rifampicin treatment on the metabolism of oestradiol and 17alpha-ethinyloestradiol by human liver microsomes","volume":"8","author":"Bolt","year":"1975","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0895","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0163-7258(79)90044-5","article-title":"Interactions between oral contraceptives and other drugs","volume":"7","author":"Breckenridge","year":"1979","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.maturitas.2022.08.008_bb0900","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1200\/JCO.1993.11.12.2417","article-title":"Phase I\/pharmacokinetic study of high-dose progesterone and doxorubicin","volume":"11","author":"Christen","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0905","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0037-1614503","article-title":"Interference with oral anticoagulant treatment by oestrogen\u2013influence of oestrogen administration route","volume":"81","author":"Cotton","year":"1999","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb0910","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1528-1157.1979.tb04834.x","article-title":"Do anticonvulsants reduce the efficacy of oral contraceptives?","volume":"20","author":"Coulam","year":"1979","journal-title":"Epilepsia."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0915","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0010-7824(86)90028-4","article-title":"The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids","volume":"33","author":"Crawford","year":"1986","journal-title":"Contraception."},{"issue":"6200","key":"10.1016\/j.maturitas.2022.08.008_bb0920","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/bmj.2.6200.1260","article-title":"Interaction between anticoagulants and contraceptives: an unsuspected finding","volume":"2","author":"de Teresa","year":"1979","journal-title":"Br. Med. J."},{"issue":"27","key":"10.1016\/j.maturitas.2022.08.008_bb0925","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1200\/JCO.2006.09.4318","article-title":"Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users","volume":"25","author":"Decensi","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0930","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/cmt.5.2.151.155","article-title":"Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study","volume":"5","author":"Dew","year":"2002","journal-title":"Climacteric."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0935","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0010-7824(85)90062-9","article-title":"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents","volume":"31","author":"Diamond","year":"1985","journal-title":"Contraception."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0940","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.maturitas.2006.06.010","article-title":"Tibolone (Livial\u00ae) enhances warfarin-induced anticoagulation in postmenopausal women","volume":"56","author":"Elbers","year":"2007","journal-title":"Maturitas."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb0945","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.1984.44","article-title":"Effects of oral contraceptives on diazepam-induced psychomotor impairment","volume":"35","author":"Ellinwood","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7273","key":"10.1016\/j.maturitas.2022.08.008_bb0950","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/bmj.321.7273.1382","article-title":"Drug points: apparent interaction between warfarin and levonorgestrel used for emergency contraception","volume":"321","author":"Ellison","year":"2000","journal-title":"BMJ."},{"issue":"5639","key":"10.1016\/j.maturitas.2022.08.008_bb0955","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/bmj.1.5639.294","article-title":"Epilepsy and oral contraception","volume":"1","author":"Espir","year":"1969","journal-title":"Br. Med. J."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb0960","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00542149","article-title":"Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone","volume":"26","author":"Frey","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0965","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1592\/phco.26.6.881","article-title":"Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene","volume":"26","author":"Garwood","year":"2006","journal-title":"Pharmacotherapy."},{"issue":"Suppl. 3","key":"10.1016\/j.maturitas.2022.08.008_bb0970","first-page":"76","article-title":"Clomipramine and oral contraceptives: an interaction study--clinical findings","volume":"8","author":"Gringras","year":"1980","journal-title":"J. Int. Med. Res."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb0975","first-page":"127","article-title":"Interaction of modafinil and clomipramine as comedication in a narcoleptic patient","volume":"21","author":"Gr\u00f6zinger","year":"1998","journal-title":"Clin. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.maturitas.2022.08.008_bb0980","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/0959-8049(94)00213-O","article-title":"Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group","volume":"30A","author":"Gundersen","year":"1994","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb0985","first-page":"23","article-title":"Failure of oral contraceptive with rifampicin","volume":"15","author":"Gupta","year":"1980","journal-title":"Med. J. Zambia"},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb0990","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2125.2003.01933.x","article-title":"Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity","volume":"56","author":"H\u00e4rtter","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb0995","series-title":"Important New Safety Information Concerning the Antiepileptic, Lamotrigina, September 27","author":"Health Canada","year":"2004"},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1000","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2165\/00003495-197612060-00003","article-title":"Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications","volume":"12","author":"Hempel","year":"1976","journal-title":"Drugs."},{"issue":"8","key":"10.1016\/j.maturitas.2022.08.008_bb1005","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1177\/0091270008318669","article-title":"The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism","volume":"48","author":"Hilli","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1010","first-page":"174","article-title":"Effets contrariants de la rifampicine sur les contraceptifs oraux: a propos de trois grossesses non desiree chez trois malades","volume":"2","author":"Hirsch","year":"1975","journal-title":"Revue fran\u00e7aise des maladies respiratoires"},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb1015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2125.1982.tb01381.x","article-title":"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam","volume":"13","author":"Jochemsen","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.maturitas.2022.08.008_bb1020","first-page":"88","article-title":"Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics of clomipramine and its desmethyl metabolite during chronic dosing","volume":"8","author":"John","year":"1980","journal-title":"J. Int. Med. Res."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0010-7824(80)90034-7","article-title":"A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs","volume":"21","author":"Joshi","year":"1980","journal-title":"Contraception."},{"issue":"11","key":"10.1016\/j.maturitas.2022.08.008_bb1030","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.2600681106","article-title":"Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol","volume":"68","author":"Jusko","year":"1979","journal-title":"J. Pharm. Sci."},{"issue":"5801","key":"10.1016\/j.maturitas.2022.08.008_bb1035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/bmj.1.5801.686-c","article-title":"Unplanned pregnancy in an epileptic","volume":"1","author":"Kenyon","year":"1972","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jama.1972.03210060052018","article-title":"Estrogen-imipramine interaction","volume":"222","author":"Khurana","year":"1972","journal-title":"JAMA."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1045","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1528-1157.1992.tb01773.x","article-title":"Possible interaction between oxcarbazepine and an oral contraceptive","volume":"33","author":"Klosterskov Jensen","year":"1992","journal-title":"Epilepsia."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb1050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jwh.2012.3479","article-title":"Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study","volume":"22","author":"Kornstein","year":"2013","journal-title":"J. Women\u2019s Health (Larchmt)"},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1055","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1176\/ajp.141.5.696","article-title":"Tricyclic-induced akathisia in patients taking conjugated estrogens","volume":"141","author":"Krishnan","year":"1984","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1060","first-page":"270","article-title":"Rifampicin und Ovulationshemmer [Rifampicin and oral contraceptives (author\u2019s transl)]","volume":"28","author":"Kropp","year":"1974","journal-title":"Prax. Pneumol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb1065","first-page":"167","article-title":"Examination of the potential interaction between ketoconazole (Nizoral) and oral contraceptives with special regard to products of low hormone content (Rigevidon, Anteovin)","volume":"34","author":"Kov\u00e1cs","year":"1986","journal-title":"Ther. Hung."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1070","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1176\/ajp.141.5.696","article-title":"Tricyclic-induced akathisia in patients taking conjugated estrogens","volume":"141","author":"Krishnan","year":"1984","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/clpt.1985.218","article-title":"Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction","volume":"38","author":"Kroboth","year":"1985","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1080","series-title":"[Rifampicin and oral contraceptives (author\u2019s transl)]. [German]. Praxis der Pneumologie vereinigt mit Der Tuberkulosearzt","first-page":"270","volume":"28","author":"Kropp","year":"1974"},{"issue":"11","key":"10.1016\/j.maturitas.2022.08.008_bb1085","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.1968.03140110061012","article-title":"Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients","volume":"203","author":"Kutt","year":"1968","journal-title":"JAMA."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1090","first-page":"181","article-title":"L\u2019effet antipilule de la rifampicine","volume":"1181","author":"Lafaix","year":"1976","journal-title":"M\u00e9d. Hyg."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb1095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2125.1999.00891.x","article-title":"Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids","volume":"47","author":"Laine","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.maturitas.2022.08.008_bb1100","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone","volume":"38","author":"LeBel","year":"1998","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.maturitas.2022.08.008_bb1105","first-page":"88","article-title":"Plasma level studies of clomipramine and desmethylclomipramine following intravenous infusions of clomipramine in depressive patients","volume":"53","author":"Luscombe","year":"1977","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1471-0528.2003.02035.x","article-title":"Interaction between hormone replacement therapy preparations and oral anticoagulant therapy","volume":"11088","author":"McLintock","year":"2003","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1115","first-page":"297","article-title":"Zeitverlauf der hemmung der coffeinelimination unter dem einflu\u00df des oralen depotkontrazeptivum Deposiston\u00ae","volume":"113","author":"Meyer","year":"1991","journal-title":"Zentralbl. Gynakol."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2125.1983.tb02207.x","article-title":"Influence of sex and oral contraceptive steroids on paracetamol metabolism","volume":"16","author":"Miners","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb1125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/clpt.1983.127","article-title":"Effects of oral contraceptive steroids on acetaminophen metabolism and elimination","volume":"34","author":"Mitchell","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1210\/jcem-23-3-261","article-title":"Potentiation of the biologic effect of administered cortisol by estrogen treatment","volume":"23","author":"Nelson","year":"1963","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"33","key":"10.1016\/j.maturitas.2022.08.008_bb1135","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1055\/s-0028-1107071","article-title":"Wirkung von Rifampicin auf den Menstruationszyklus und die Ostrogenausscheidung bei Einnahme oraler Kontrazeptiva [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives]","volume":"98","author":"Nocke-Finck","year":"1973","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb1140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00228-002-0469-y","article-title":"Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline","volume":"58","author":"Palovaara","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1145","first-page":"603","article-title":"Impaired elimination of caffeine by oral contraceptive steroids","volume":"95","author":"Patwardhan","year":"1980","journal-title":"J. Lab. Clin. Med."},{"issue":"965","key":"10.1016\/j.maturitas.2022.08.008_bb1150","first-page":"436","article-title":"Pregnancy associated with a combined oral contraceptive and itraconazole","volume":"106","author":"Pillans","year":"1993","journal-title":"N. Z. Med. J."},{"issue":"12","key":"10.1016\/j.maturitas.2022.08.008_bb1155","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/0961203306071706","article-title":"Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil)","volume":"15","author":"Pisoni","year":"2006","journal-title":"Lupus."},{"issue":"9","key":"10.1016\/j.maturitas.2022.08.008_bb1160","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/00912709922008560","article-title":"Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women","volume":"39","author":"Pollock","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1165","first-page":"143","article-title":"Estrogen may well affect the response to antidepressants","volume":"219","author":"Prange","year":"1972","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.maturitas.2022.08.008_bb1170","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0033-3182(89)72262-3","article-title":"Interactions between carbamazepine and birth control pills","volume":"30","author":"Rapport","year":"1989","journal-title":"Psychosomatics."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb1175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00548769","article-title":"Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids","volume":"26","author":"Rietveld","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1180","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cpt1979256826","article-title":"Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives","volume":"25","author":"Roberts","year":"1979","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1185","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2125.1987.tb03107.x","article-title":"Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol","volume":"23","author":"Rogers","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.maturitas.2022.08.008_bb1190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(01)00305-9","article-title":"Lamotrigine plasma levels reduced by oral contraceptives","volume":"47","author":"Sabers","year":"2001","journal-title":"Epilepsy Res."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1195","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/cpt196785670","article-title":"Effect of oral contraceptives on vitamin K-dependent clotting activity","volume":"8","author":"Schrogie","year":"1967","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.maturitas.2022.08.008_bb1200","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/0091270005280851","article-title":"Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail","volume":"45","author":"Shelepova","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb1205","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0002-9378(98)80016-1","article-title":"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives","volume":"178","author":"Sinofsky","year":"1998","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"12","key":"10.1016\/j.maturitas.2022.08.008_bb1210","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jama.1976.03270130044027","article-title":"Rifampin, oral contraceptives, and pregnancy","volume":"236","author":"Skolnick","year":"1976","journal-title":"JAMA."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1215","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jama.1973.03220050060032","article-title":"Mechanism of estrogen-imipramine interaction","volume":"223","author":"Somani","year":"1973","journal-title":"JAMA."},{"issue":"Suppl. 133","key":"10.1016\/j.maturitas.2022.08.008_bb1220","first-page":"37","article-title":"Oxcarbazepine and oral contraceptives","volume":"82","author":"Sonnen","year":"1990","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.maturitas.2022.08.008_bb1225","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/clpt.1984.240","article-title":"Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics","volume":"36","author":"Stoehr","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.maturitas.2022.08.008_bb1230","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb1235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00545966","article-title":"Effect of chronic oral contraceptive steroids on theophylline disposition","volume":"23","author":"Tornatore","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.maturitas.2022.08.008_bb1240","first-page":"146","article-title":"Verstoring van de pilcyclus tijdens het gelijktijdig gebruik van itraconazol en orale anticonceptiva [Pill cycle disturbance in simultaneous use of itraconazole and oral contraceptives]","volume":"142","author":"van Puijenbroek","year":"1998","journal-title":"Ned. Tijdschr. Geneeskd."},{"issue":"9312","key":"10.1016\/j.maturitas.2022.08.008_bb1245","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S0140-6736(02)08159-X","article-title":"Tamoxifen for breast cancer among hysterectomised women","volume":"359","author":"Veronesi","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.maturitas.2022.08.008_bb1250","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2020.01.005","article-title":"European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","volume":"134","author":"Rees","year":"2020","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.maturitas.2022.08.008_bb1255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.maturitas.2015.02.003","article-title":"EMAS position statement: The ten point guide to the integral management of menopausal health","volume":"81","author":"Neves-E-Castro","year":"2015","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.maturitas.2022.08.008_bb1260","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.maturitas.2014.11.007","article-title":"Spanish consensus on premature menopause","volume":"80","author":"Mendoza","year":"2015","journal-title":"Maturitas"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512222001797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512222001797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:21:11Z","timestamp":1759915271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512222001797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":252,"alternative-id":["S0378512222001797"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2022.08.008","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2022.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}